Product logins

Find logins to all Clarivate products below.


Squamous Cell Carcinoma of the Head and Neck – Epidemiology – Europe

Clarivate Epidemiologys coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of squamous cell carcinoma of the head and neck for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and over a period of 10 years for the other countries covered in this report. In addition to forecast prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

Clarivate Epidemiologys squamous cell carcinoma of the head and neck forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with squamous cell carcinoma of the head and neck per year?
  • Of all people diagnosed with squamous cell carcinoma of the head and neck, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of squamous cell carcinoma of the head and neck over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts over 100 squamous cell carcinoma of the head and neck patient populations, as follows:

  • Locoregionally advanced non-nasopharyngeal drug-treated.
  • Firstline metatstatic DTP – nasopharynx.
  • Other SCCHN – stage IVB.
  • Diagnosed incident cases – nasopharynx – stage IVA.
  • Diagnosed prevalent cases of HPV-negative oropharynx cancer.
  • Diagnosed incident cases – nasopharynx EBVnegative.
  • Secondline non-nasopharyngeal drug-treated.
  • Diagnosed incident cases – nasopharynx cancer.
  • … and many more (details available on request).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…